ArticleJournal of the National Cancer Institute2009
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas.
Article in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Trial
- C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- Altered folate availability modifies the molecular environment of the human colorectum: implications for colorectal carcinogenesis.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- Review
- Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer.JAMA oncology · 2023Article
- Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials.The journal of nutrition, health & aging · 2021Article
- CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.Clinical practice (London, England) · 2021Article
- One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study.The British journal of nutrition · 2020Article
- Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers.Journal of the National Cancer Institute · 2016Article
- Factors Associated with Multiple Biomarkers of Systemic Inflammation.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Article
- Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women.Cancer prevention research (Philadelphia, Pa.) · 2016Article
- C-reactive protein as a marker of complicated diverticulitis in patients on anti-inflammatory medications.Techniques in coloproctology · 2014Article
- Circulating soluble cytokine receptors and colorectal cancer risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- Dietary methyl donor depletion protects against intestinal tumorigenesis in Apc(Min/+) mice.Cancer prevention research (Philadelphia, Pa.) · 2012Article
- Article
- Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.Gastroenterology · 2011Article
- Biomarkers of Inflammation and Immune Function and Risk of Colorectal Cancer.Current colorectal cancer reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, reduced recurrence of colorectal adenomas. This study examined whether treatment effects on inflammation markers explained the trial results. The trial had a factorial design with three aspirin (placebo, 81, and 325 mg/d) and two folic acid (placebo and 1 mg/d) groups. There were 884 subjects who had colonoscopic evaluation for adenomas at year 3 and plasma levels of C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), soluble TNF receptor type II (sTNF-R2), and IL-1 receptor antagonist (IL-1Ra) measured at baseline and year 3. Among individuals not receiving folic acid, there was a 4% decrease (mean ratio of year 3 to baseline levels = 0.96, 95% confidence interval [CI] = 0.82 to 1.14) in CRP for a period of 3 years in the 325 mg of aspirin group vs a 20% increase (mean ratio = 1.20, 95% CI = 1.03 to 1.41) in the placebo group (P = .027). By contrast, the reverse was observed among individuals who also received folic acid (P(interaction) = .013). Changes in inflammation markers were not associated with adenoma recurrence. Low-dose aspirin (325 mg/d) is beneficial in stabilizing CRP levels, which may be abrogated by folate. Nevertheless, inflammation markers do not mediate the chemopreventive effect of aspirin on colorectal adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.